Affordable Access

Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.

Authors
  • Hur, Hoon
  • Park, Ae-Ryoung
  • Jee, Sung-Bae
  • Jung, Seung-Eun
  • Kim, Wook
  • Jeon, Hae-Myung
Type
Published Article
Journal
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Co
Publication Date
Oct 21, 2008
Volume
14
Issue
39
Pages
6096–6099
Identifiers
PMID: 18932293
Source
Medline
License
Unknown

Abstract

The molecular targets of sunitinib are receptor tyrosine kinases (RTKs), and this drug has also been known to exert blocking effects on the activation of KIT, which is similar to the mechanism of action of imatinib. Moreover, sunitinib has an additional anti-angiogenic effect through its inhibition of the vascular endothelial growth factor receptor activation. We report here a 70-year-old patient diagnosed with a recurrent gastrointestinal stromal tumor (GIST), which invaded the transverse colon and led to a perforation during sunitinib treatment. A computed tomography scan and 3-dimensional reconstruction showed necrosis of the recurrent hepatic mass and perforation of the invaded transverse colon. After percutaneous drainage of the intraperitoneal abscess, antibiotic treatment and restricted diet, the condition of the patient improved. The present case is the first to report that sunitinib, which is administered to treat GIST resistant to imatinib, can cause unexpected colon perforation and subsequent peritonitis.

Report this publication

Statistics

Seen <100 times